DxDirect is a combination of DxCollect, a novel nucleic acid stabilization buffer, and Chemical Ligation Dependent Probe Amplification (CLPA), a robust detection chemistry. Together, DxDirect provides quantitative, multiplexed genomics at lower cost than any other system for research and pre-clinical studies.


By combining DxCollect, a novel RNA stabilization buffer, and a robust detection chemistry known as Chemical Ligation Dependent Probe Amplification (CLPA), DxDirect provides a unique unified platform for gene expression direct from blood for research and preclinical studies.


DxTerity Announces $7.5 Million in Financing from SWK Funding

Duke Awarded $10.4 Million Contract To Continue Developing Radiation Test

DxTerity Diagnostics featured in Clinical Omics

LA Business Journal - Focus on Healthcare

DxTerity Launches DxDirect Reagent Kits for Research

DxTerity Receives CAP Accreditation

DxTerity Announces CLIA Licensure

REDI-DX Radiation Test Performs Well in NATO Study

REDI-Dx Wins 2013 Product of the Year Award

DxTerity Wins SBIR to Develop Radiation Toxicity Test

DxTerity REDI-Dx Functional Exercise with Scottsdale Health and GER911

DxTerity Launches REDI-Dx Reagent Kits for Research

DxTerity Opens New Lab

DxTerity Wins SBIR Grant to Develop FFPE Gene Expression Assays

DxTerity Acquires SourceMDx Assets